Important differences have emerged, including that male breast cancer prognosis is significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor, and that male breast cancer is not congruent with female breast cancer [6]. Here, CYP19A1 is linked to breast carcinoma.